Aclaris Therapeutics Revenue and Competitors

Claim your profile

Location

$219.9M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Aclaris Therapeutics's estimated annual revenue is currently $6.8M per year.(i)
  • Aclaris Therapeutics received $86.3M in venture funding in August 2017.
  • Aclaris Therapeutics's estimated revenue per employee is $105,231
  • Aclaris Therapeutics's total funding is $219.9M.
  • Aclaris Therapeutics's current valuation is $661.9M. (January 2022)

Employee Data

  • Aclaris Therapeutics has 65 Employees.(i)
  • Aclaris Therapeutics grew their employee count by 38% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$41.4M206-6%N/AN/A
#2
$62.5M31135%N/AN/A
#3
$4.7M5730%N/AN/A
#4
$1110.5M5525-10%N/AN/A
#5
$45.4M226-1%N/AN/A
#6
$11.7M5816%N/AN/A
#7
$13.7M6842%N/AN/A
#8
$17.3M8637%N/AN/A
#9
$45.5M21912%N/AN/A
#10
$4.8M58-13%N/AN/A

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$219.9M

Total Funding

65

Number of Employees

$6.8M

Revenue (est)

38%

Employee Growth %

$661.9M

Valuation

N/A

Accelerator

Aclaris Therapeutics News

2022-04-20 - Zacks: Analysts Expect Aclaris Therapeutics, Inc. (NASDAQ ...

Aclaris Therapeutics posted earnings of ($0.57) per share in the same quarter last year, which would indicate a positive year-over-year growth...

2022-04-17 - Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average ...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of “Buy” by Analysts. Posted by admin on Apr 17th, 2022.

2022-04-13 - Financial Contrast: NeuroSense Therapeutics (NASDAQ ...

This is a breakdown of current recommendations for NeuroSense Therapeutics and Aclaris Therapeutics, as reported by MarketBeat.com. Sell Ratings...

2019-09-08 - Aclaris to lay off 86 employees in restructuring to extend cash

Aclaris Therapeutics will lay off 86 employees and end certain development programs as it restructures to extend cash for operations, the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.8M6510%N/A
#2
$7.1M6683%N/A
#3
$15.1M6638%N/A
#4
$17.3M676%N/A
#5
$3.5M676%N/A

Aclaris Therapeutics Funding

DateAmountRoundLead InvestorsReference
2012-10-25$21.0MAVivo Ventures, Fidelity BiosciencesArticle
2014-10-03$21.0MBVivo VenturesArticle
2015-09-11$10.0MASwitchArticle
2016-06-17$20.0MUndisclosedArticle
2016-11-18$65.0MUndisclosedJefferies LLCArticle
2016-11-21$85.2MUndisclosedJefferies LLC,Article
2017-08-14$86.3MUndisclosedJefferies LLCArticle